Recent Therapeutic Gene Editing Applications to Genetic Disorders

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2024 May 24

PMID 38785523

Authors

Eric Deneault

Affiliations

Soon will be listed here.

Abstract

Recent years have witnessed unprecedented progress in therapeutic gene editing, revolutionizing the approach to treating genetic disorders. In this comprehensive review, we discuss the progression of milestones leading to the emergence of the clustered regularly interspaced short palindromic repeats (CRISPR)-based technology as a powerful tool for precise and targeted modifications of the human genome. CRISPR-Cas9 nuclease, base editing, and prime editing have taken center stage, demonstrating remarkable precision and efficacy in targeted ex vivo and in vivo genomic modifications. Enhanced delivery systems, including viral vectors and nanoparticles, have further improved the efficiency and safety of therapeutic gene editing, advancing their clinical translatability. The exploration of CRISPR-Cas systems beyond the commonly used Cas9, such as the development of Cas12 and Cas13 variants, has expanded the repertoire of gene editing tools, enabling more intricate modifications and therapeutic interventions. Outstandingly, prime editing represents a significant leap forward, given its unparalleled versatility and minimization of off-target effects. These innovations have paved the way for therapeutic gene editing in a multitude of previously incurable genetic disorders, ranging from monogenic diseases to complex polygenic conditions. This review highlights the latest innovative studies in the field, emphasizing breakthrough technologies in preclinical and clinical trials, and their applications in the realm of precision medicine. However, challenges such as off-target effects and ethical considerations remain, necessitating continued research to refine safety profiles and ethical frameworks.

Citing Articles

Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication.

Borrajo A Life (Basel). 2025; 15(2).

PMID: 40003685 PMC: 11856976. DOI: 10.3390/life15020276.

A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders.

Deokate N, Acharya S, Patil R, Shaikh S, Karwa V Cureus. 2024; 16(8):e67506.

PMID: 39310492 PMC: 11416137. DOI: 10.7759/cureus.67506.

Perspectives on CRISPR Genome Editing to Prevent Prion Diseases in High-Risk Individuals.

Medd M, Cao Q Biomedicines. 2024; 12(8).

PMID: 39200190 PMC: 11352000. DOI: 10.3390/biomedicines12081725.

References

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

Duan W, Guo M, Yi L, Liu Y, Li Z, Ma Y . The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2019; 27(3-4):157-169. DOI: 10.1038/s41434-019-0116-1. View

Li G, Jin M, Li Z, Xiao Q, Lin J, Yang D . Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. J Clin Invest. 2022; 133(3). PMC: 9888377. DOI: 10.1172/JCI162809. View

Urnov F, Miller J, Lee Y, Beausejour C, Rock J, Augustus S . Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005; 435(7042):646-51. DOI: 10.1038/nature03556. View

Chen C, Deneault E, Abdian N, You Z, Sirois J, Nicouleau M . Generation of patient-derived pluripotent stem cell-lines and CRISPR modified isogenic controls with mutations in the Parkinson's associated GBA gene. Stem Cell Res. 2022; 64:102919. DOI: 10.1016/j.scr.2022.102919. View

Seo J, Shin J, Lee J, Kim D, Hwang H, Nam B . DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice. Commun Biol. 2023; 6(1):466. PMC: 10147674. DOI: 10.1038/s42003-023-04829-8. View

Koblan L, Arbab M, Shen M, Hussmann J, Anzalone A, Doman J . Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning. Nat Biotechnol. 2021; 39(11):1414-1425. PMC: 8985520. DOI: 10.1038/s41587-021-00938-z. View

Nishiyama T, Zhang Y, Cui M, Li H, Sanchez-Ortiz E, McAnally J . Precise genomic editing of pathogenic mutations in rescues dilated cardiomyopathy. Sci Transl Med. 2022; 14(672):eade1633. PMC: 10088465. DOI: 10.1126/scitranslmed.ade1633. View

Jansen R, van Embden J, Gaastra W, Schouls L . Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. DOI: 10.1046/j.1365-2958.2002.02839.x. View

10.

Adler B, Trinidad M, Bellieny-Rabelo D, Zhang E, Karp H, Skopintsev P . CasPEDIA Database: a functional classification system for class 2 CRISPR-Cas enzymes. Nucleic Acids Res. 2023; 52(D1):D590-D596. PMC: 10767948. DOI: 10.1093/nar/gkad890. View

11.

Cappelluti M, Mollica Poeta V, Valsoni S, Quarato P, Merlin S, Merelli I . Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature. 2024; 627(8003):416-423. PMC: 10937395. DOI: 10.1038/s41586-024-07087-8. View

12.

Han J, Lee Y, Lee J, Chung H, Lee G, Nam Y . genome editing using 244- LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice. Mol Ther Nucleic Acids. 2023; 34:102050. PMC: 10616378. DOI: 10.1016/j.omtn.2023.102050. View

13.

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

14.

Song C, Wang D, Jiang T, OConnor K, Tang Q, Cai L . In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther. 2018; 29(8):853-860. PMC: 6110121. DOI: 10.1089/hum.2017.225. View

15.

Newby G, Yen J, Woodard K, Mayuranathan T, Lazzarotto C, Li Y . Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021; 595(7866):295-302. PMC: 8266759. DOI: 10.1038/s41586-021-03609-w. View

16.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

17.

Cui T, Cai B, Tian Y, Liu X, Liang C, Gao Q . Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR-Cas12f1 System Delivered with All-in-One Adeno-Associated Virus. Adv Sci (Weinh). 2024; 11(19):e2308095. PMC: 11109646. DOI: 10.1002/advs.202308095. View

18.

Smith H, WILCOX K . A restriction enzyme from Hemophilus influenzae. I. Purification and general properties. J Mol Biol. 1970; 51(2):379-91. DOI: 10.1016/0022-2836(70)90149-x. View

19.

Zetsche B, Gootenberg J, Abudayyeh O, Slaymaker I, Makarova K, Essletzbichler P . Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015; 163(3):759-71. PMC: 4638220. DOI: 10.1016/j.cell.2015.09.038. View

20.

Doman J, Pandey S, Neugebauer M, An M, Davis J, Randolph P . Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell. 2023; 186(18):3983-4002.e26. PMC: 10482982. DOI: 10.1016/j.cell.2023.07.039. View